Therapeutic biopharma KaloBios sets terms for $50 million IPO
KaloBios, a biopharmaceutical company focused on therapeutics that treat respiratory diseases and cancer, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $50 million by offering 3.9 million shares at a price range of $12 to $14. At the midpoint of the proposed range, KaloBios would command a market value of $239 million. KaloBios, which was founded in 2001 and booked $12 million in contract revenues for the 12 months ended 9/30/2012, plans to list on the NASDAQ under the symbol KBIO. Leerink Swann is the sole bookrunner on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.